Researchers leading the University of Oxford’s Com-COV3 study have delivered results from a study researching the immune response and side-effect profile of ‘mixed’ two-dose COVID-19 vaccine schedules.
The trial unfolded in adolescents aged between 12 and 16 years who received either a full or a one-third dose of the Pfizer-BioNTech COVID-19 vaccine – or a full dose of the Novavax vaccine at least eight weeks after a first full dose of the Pfizer-BioNTech vaccine…
